Glecaprevir

Drug Profile

Glecaprevir

Alternative Names: ABT-493; Next-generation HCV protease inhibitor - AbbVie/Enanta

Latest Information Update: 18 May 2016

Price : $50

At a glance

  • Originator AbbVie; Enanta Pharmaceuticals
  • Developer AbbVie
  • Class Antivirals; Aza compounds; Cyclic ethers; Cyclopentanes; Cyclopropanes; Quinoxalines; Small molecules
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 18 Apr 2016 Pooled efficacy and adverse event data from the phase II SURVEYOR-I and SURVEYOR-2 trials for Hepatitis C presented at The International Liver Congress™ 2016 (ILC-2016)
  • 15 Apr 2016 Updated efficacy data from a phase II MAGELLAN 1 study were reported by Enanta Pharmaceuticals
  • 15 Apr 2016 Updated safety and efficacy data from a phase II MAGELLAN 1 study were presented at the International Liver Congress™ (ILC-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top